The India–European Union Free Trade Agreement (FTA) is set to provide Indian pharmaceutical and medical technology companies access to a $572 billion EU healthcare market, creating new export opportunities across regulated markets.

Under the agreement, Indian manufacturers will benefit from tariff liberalisation and preferential market access, supporting exports of formulations, APIs, biosimilars, vaccines, diagnostics and medical devices to EU member states. The reduced trade barriers are expected to improve price competitiveness and ease entry into one of the world’s largest healthcare markets.

For pharma companies, the FTA strengthens export prospects in high-value regulated segments, while medical device makers are expected to benefit from improved access to European hospitals and healthcare systems. The agreement also supports scale-up of export-oriented manufacturing.

India’s pharmaceutical exports to the EU already include formulations, biosimilars and APIs, with shipments nearing USD 6 billion in FY25. Expanded access under the FTA is expected to further accelerate trade volumes.

The agreement positions Indian pharma and medtech companies for long-term export growth and deeper integration into global healthcare supply chains.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!